X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with ASTRAZENECA PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs ASTRAZENECA PHARMA - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS ASTRAZENECA PHARMA IPCA LABS/
ASTRAZENECA PHARMA
 
P/E (TTM) x 41.9 105.3 39.8% View Chart
P/BV x 3.2 15.0 21.4% View Chart
Dividend Yield % 0.2 0.0 -  

Financials

 IPCA LABS   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    IPCA LABS
Mar-17
ASTRAZENECA PHARMA
Mar-14
IPCA LABS/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs6431,285 50.0%   
Low Rs503634 79.3%   
Sales per share (Unadj.) Rs254.4189.6 134.2%  
Earnings per share (Unadj.) Rs16.1-0.2 -7,892.8%  
Cash flow per share (Unadj.) Rs29.83.8 774.5%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs194.668.6 283.4%  
Shares outstanding (eoy) m126.2025.00 504.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.35.1 44.5%   
Avg P/E ratio x35.7-4,712.7 -0.8%  
P/CF ratio (eoy) x19.2249.6 7.7%  
Price / Book Value ratio x2.914.0 21.1%  
Dividend payout %6.20-   
Avg Mkt Cap Rs m72,30023,988 301.4%   
No. of employees `00013.31.6 853.3%   
Total wages/salary Rs m6,9601,605 433.7%   
Avg. sales/employee Rs Th2,413.53,040.2 79.4%   
Avg. wages/employee Rs Th523.21,029.2 50.8%   
Avg. net profit/employee Rs Th152.4-3.3 -4,669.2%   
INCOME DATA
Net Sales Rs m32,1064,740 677.4%  
Other income Rs m22692 245.1%   
Total revenues Rs m32,3324,832 669.2%   
Gross profit Rs m4,448-130 -3,426.7%  
Depreciation Rs m1,730101 1,709.0%   
Interest Rs m2410-   
Profit before tax Rs m2,703-139 -1,946.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0139 0.0%   
Tax Rs m6755 13,265.2%   
Profit after tax Rs m2,028-5 -39,842.8%  
Gross profit margin %13.9-2.7 -505.9%  
Effective tax rate %25.0-3.7 -681.6%   
Net profit margin %6.3-0.1 -5,881.8%  
BALANCE SHEET DATA
Current assets Rs m17,3402,726 636.0%   
Current liabilities Rs m9,5592,435 392.6%   
Net working cap to sales %24.26.1 394.2%  
Current ratio x1.81.1 162.0%  
Inventory Days Days10074 136.0%  
Debtors Days Days5741 139.5%  
Net fixed assets Rs m20,7791,035 2,007.1%   
Share capital Rs m25250 504.8%   
"Free" reserves Rs m24,499942 2,599.6%   
Net worth Rs m24,5531,716 1,430.8%   
Long term debt Rs m3,5170-   
Total assets Rs m39,5954,156 952.7%  
Interest coverage x12.2NM-  
Debt to equity ratio x0.10-  
Sales to assets ratio x0.81.1 71.1%   
Return on assets %5.7-0.1 -4,678.6%  
Return on equity %8.3-0.3 -2,784.6%  
Return on capital %10.50-  
Exports to sales %48.65.7 853.3%   
Imports to sales %14.26.5 220.3%   
Exports (fob) Rs m15,617270 5,779.9%   
Imports (cif) Rs m4,571306 1,492.3%   
Fx inflow Rs m15,617375 4,169.1%   
Fx outflow Rs m5,828470 1,239.5%   
Net fx Rs m9,790-96 -10,245.6%   
CASH FLOW
From Operations Rs m2,764-8 -34,125.9%  
From Investments Rs m-1,432-146 982.6%  
From Financial Activity Rs m-1,591862 -184.6%  
Net Cashflow Rs m-259709 -36.5%  

Share Holding

Indian Promoters % 45.9 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 11.4 0.3 3,800.0%  
FIIs % 25.3 15.7 161.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 9.1 191.2%  
Shareholders   36,892 12,856 287.0%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   GLENMARK PHARMA  FULFORD INDIA  MERCK LTD  AJANTA PHARMA  UNICHEM LAB  

Compare IPCA LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Feb 16, 2018 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS - PLETHICO PHARMA COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS